文献速递焦虑、强迫与应激相关障碍

美金刚治疗拔毛癖与抓皮障碍的双盲安慰剂对照研究

Double-Blind Placebo-Controlled Study of Memantine in Trichotillomania and Skin-Picking Disorder.
PubMed 文献 · Am J Psychiatry · 2023-02-22

结果显示美金刚组在NIMH症状严重度量表等指标上显著优于安慰剂,60.5%的患者「显著或非常显著改善」,安慰剂组仅8.3%,且不良反应无显著差异。

要点

  • 美金刚8周治疗显著改善拔毛和抓皮症状,NNT=1.9提示疗效较高。
  • 美金刚组60.5%达「显著或非常显著改善」,安慰剂组仅8.3%。
  • 不良反应在美金刚组与安慰剂组间无显著差异,耐受性良好。

核心结论

  • 美金刚治疗拔毛癖和抓皮障碍在减少症状方面优于安慰剂,且耐受性良好。

主要发现

  • 美金刚组在NIMH拔毛癖症状严重度量表(修改版含抓皮)上较安慰剂组有显著改善(治疗×时间交互作用)。
  • 美金刚组在Sheehan残疾量表和临床总体印象严重度量表上亦显著优于安慰剂。
  • 研究终点时美金刚组60.5%为「显著或非常显著改善」,安慰剂组为8.3%(NNT=1.9)。
  • 不良事件在两组间无显著差异。

关键数值与推荐

  • 主要结局为NIMH拔毛癖症状严重度量表(修改版含抓皮)的治疗相关变化。
  • 美金刚组60.5%达「显著或非常显著改善」,安慰剂组8.3%,NNT=1.9。

临床怎么用

  • 对于拔毛癖或抓皮障碍成人患者,美金刚(10-20 mg/日)可作为8周治疗的循证选择,疗效较高且耐受性良好。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Trichotillomania and skin-picking disorder are underrecognized and often disabling conditions in which individuals repeatedly pull at their hair or pick at their skin, leading to noticeable hair loss or tissue damage. To date there is a severe paucity of evidence-based treatments for these conditions. In this study, the authors sought to determine whether memantine, a glutamate modulator, is more effective than placebo in reducing hair-pulling and skin-picking behavior. METHODS: One hundred adults with trichotillomania or skin-picking disorder (86 women; mean age, 31.4 years [SD=10.2]) were enrolled in a double-blind trial of memantine (dosing range, 10-20 mg/day) or placebo for 8 weeks. Participants were assessed with measures of pulling and picking severity. Outcomes were examined using a linear mixed-effects model. The prespecified primary outcome measure was treatment-related change on the NIMH Trichotillomania Symptom Severity Scale, modified to include skin picking. RESULTS: Compared with placebo, memantine treatment was associated with significant improvements in scores on the NIMH scale, Sheehan Disability Scale, and Clinical Global Impressions severity scale in terms of treatment-by-time interactions. At study endpoint, 60.5% of participants in the memantine group were "much or very much improved," compared with 8.3% in the placebo group (number needed to treat=1.9). Adverse events did not differ significantly between the treatment arms. CONCLUSIONS: This study found that memantine treatment resulted in statistically significant reductions in hair pulling and skin-picking symptoms compared with placebo, with relatively high efficacy (based on number needed to treat), and was well tolerated. The glutamate system may prove to be a beneficial target in the treatment of compulsive behaviors.

来源:Am J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Grant JE, Chesivoir E, Valle S, et al. Double-Blind Placebo-Controlled Study of Memantine in Trichotillomania and Skin-Picking Disorder. Am J Psychiatry. 2023. PMID: 36856701. doi:10.1176/appi.ajp.20220737

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。